Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with inflammatory bowel disease
High‐treatment‐dose vitamin D (greater than 1000 IU/day) showed no clear difference in clinical relapse at end of study (52 weeks) compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in mortality at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
1 finding from 1 review
Drowning (fatal and non‐fatal) · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Unsafe water exposure · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of unintentional injury · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Program safety · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cost‐effectiveness · 9‐ to 47‐month‐old children in LMICs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Drowning mortality rate · 9‐ to 47‐month‐old children in LMICs
It is very uncertain whether day care programs changes drowning mortality rate compared with playpen provision (very low certainty).
1 finding from 1 review